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Akt is a protein that is associated with cell proliferation and is expressed at high levels in cancer cells. Some 
research indicates it may play a role in increasing the resistance of cancer cells to chemotherapy treatment. P53 is 
a tumor suppressor protein that influences the cell cycle and apoptosis. The purpose of this study was to examine 
the relationship between the expression of Akt and p53 in cancerous tissue before chemoradiation treatment, and 
the clinical response to treatment of cervical cancer patients. Twenty microscopic tissue samples were taken from 
cervical cancer biopsies obtained from patients before cancer treatment. The tissue samples were stained with p53 
and Akt antibodies via immunohistochemistry technique, to measure expression of both proteins. After completion 
of chemoradiotherapy, patients’ clinical response to treatment was determined using the pelvic control method. Our 
results revealed no correlation between expression of Akt and p53 index (P = 0.74) as well as between p53 Index 
and chemoradiotherapy clinical response (P=0.29). There was significant correlation between expression of Akt and 
cervical cancer chemoradiotherapy response (P = 0.03). There was no correlation found between p53 index and 
chemoradiotherapy clinical response (P = 0.29). High expression of Akt may related with high cell proliferation and 
resistance to chemoradiotherapy.
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INTRODUCTION
 Cervical cancer is the most common type of 
malignancy diagnosed in Indonesia. In general, 
patients seek treatment when the disease is not yet 
metastatized, but already at an advanced stage in 
its original location. In Indonesia, the treatment 
of choice for this type and stage of cancer is 
radiotherapy combined with chemotherapy or 
concurrent chemoradiotherapy (Didit & Rukmini 
2002; Mufyala & Wofson 2008).
	 Radiotherapy	provides	 significant	 curative	 and	
palliative	benefits	and	is	used	in	about	40-50%	of	all	
cases of cervical cancer (Delaney et al. 2005). The 
efficacy	of	radiotherapy	is	influenced	by	two	factors	
i.e. physical and biological factors. Two important 
biological factors are the patient’s intrinsic rate of 
cell proliferation, as well as the extent of hypoxia in 
the cancer cells (Wilson et al. 2006). Physical factors 
include cell kinetics: the rate of proliferation in cancer 
cells correlates positively with its radiosensitivity 
and death by irradiation. The risk of cancer cell 
repopulation is greater after a failure of radiation 
treatment (Wilson 2003; Eriksen et al. 2004; Pedicini 
et al. 2012).
 Akt [protein kinase B (PKB)] is a serine threonine 
protein kinase with oncogenic and anti apoptotic 
activities (Gasinska et al. 2004). This protein consists 
of Akt1, Akt2, and Akt3, all of which have been 
found to play a role in the regulation of fundamental 
cellular functions such as cell proliferation, survival 
and programmed cell death; glucose metabolism, 
ribosomal function, genetic transcription, and cell 
migration via phosphorylation of a multitude of 
substrates. Dysregulation of Akt signaling pathways 
featured in many human malignancies (Song et al. 
2005; Ree 2008; Taylor et al. 2008). In cervical 
cancer, the increased expression of Akt results in the 
Copyright © 2014 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
174     KURNIA ET AL.                                                                                                                                                 HAYATI J Biosci
transformation of normal cervical to neoplasm cell 
(Crowell et al. 2007).
 The p53 gene acts as a tumor suppressor. It 
works to regulate cell proliferation by stimulating 
transcription	 of	 other	 genes	 specific	 to	 cell	 cycle	
control (Brainwaithe & Prives 2006) and the process 
of apoptosis (Bai & Zhou 2006). Cells with a wild-
type p53 gene have normal cell cycle function, 
including the ability to shut down replication of 
abnormal DNA during the G1 to S phase. Cancer cells 
with an inactivated, or mutant p53 protein cannot 
function properly and so replication of abnormal 
DNA is not prevented. In fact, inactivation of wild-
type p53 gene represents the most common genetic 
mutation implicated in human carcinogenesis (Fei 
& El Deiry 2003; Brenna et al. 2004), and some 
researchers maintain that its over-expression, as 
detected by immunohistochemistry, indicates a worse 
prognosis in some malignancies (Wootipoom et al. 
2004; Kocak  et al. 2013; Min et al. 2014).
 Cancer cell death in radiotherapy is caused in part by 
apoptosis, a process which is also regulated by p53. A 
proposed association between Akt expression and the 
effectiveness of radiotherapy and chemoradiotherapy 
on cervical cancer is still controversial. Some studies 
report a positive correlation between Akt expression 
and prognosis/response, while others have found a 
negative correlation. In the majority of studies, the 
expression of Akt is observed qualitatively using 
immunohistochemistry method (Kim et al. 2006; 
Faried et al. 2006; Zhang & Zhang 2008; Kocak et al. 
2013). The aim of the present research was to detect 
and evaluate any relationship between the expression 
of Akt in cervical cancer tissues measured by the IRS 
(Immno Reactive Score) method and p53 index with 
cervical cancer chemoradiotherapy response.
MATERIALS AND METHODS
 Patients. Twenty consecutive subjects, were 
selected from among a whole series of 60 patients 
suffering from non-metastatic localized cervical 
carcinoma (stage IIB-IIIB). The subjects received 
a complete course of treatment, and were studied 
prospectively from July 2010 to March 2011 
(Table 1). All patients were diagnosed and treated 
by definitive and concurrent chemoradiotherapy 
at Cipto Mangunkusumo Hospital (Jakarta) and 
Hasan Sadikin Hospital (Bandung) and provided 
written informed consent. Our research protocol was 
approved by the Research and Ethical Committee 
from Faculty of Medicine, University of Indonesia. 
Clinical staging of the patients was conducted 
by speculoscopy, bimanual examination and 
cystoscopy or rectoscopy, if necessary. Abdominal 
pelvic CT scans and chest X-rays were performed 
on	 all	 patients.	Histological	 grade	was	 classified	
according to the guidelines published by the Union 
for International Cancer Control as follows: G1 well 
differentiated; G2 moderately differentiated; and G3 
poorly differentiated or undifferentiated.  All patients 
had squamous cell carcinoma tumors with 13 patients 
diagnosed at clinical stage IIB, 1 patient at stage IIIA 
and 6 patients at stage IIIB.
 Treatment. Patients were treated with a 
combination of External Beam Radiotherapy (EBRT) 
with 60Co gamma rays and 192Ir High Dose-Rate 
Intracavitary Brachytherapy (HDR-ICBT). EBRT 
Table 1. Expression of Akt, p53 index, and chemoradiotherapy clinical response in cervical cancer treated with chemoradiotherapy
ID Stage IRS of Akt p53 index Response Response group
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
IIB
IIIB
IIB
IIIB
IIB
IIB
IIIA
IIIB
IIIB
IIIB
IIB
IIIB
IIB
IIB
IIB
IIB
IIB
IIB
IIB
IIB
12
4
6
2
2
2
4
4
3
8
3
6
6
6
6
6
4
4
4
4
0.21
0.36
0.36
0.17
0.26
0.48
0.67
0.65
0.38
0.60
0.36
0.59
0.28
0.66
0.48
0.54
0.44
0.43
0.39
0.13
bad
bad
bad
good
good
good
good
good
good
bad
bad
good
bad
good
good
good
good
good
good
good
1
1
1
2
2
2
2
2
2
1
1
2
1
2
2
2
2
2
2
2
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was administered to the whole pelvis with a clinical 
target volume that included the primary cancer, 
uterus, internal iliac artery, pre sacral, external iliac 
artery,  and lower common iliac lymph nodes. This 
was	usually	achieved	by	a	“four-field	box	technique,”	
or sometimes by antero-posterior and postero-anterior 
parallel	opposed	portals.	The	usual	field	borders	for	
anterior	and	posterior	fields	were	superior	at	the	L4-
L5 inter space, inferior at the bottom of the obturator 
foramen or 2 cm distal from the tumor, and 1.5 to 
2.0	cm	lateral	to	the	bony	pelvic	wall.	Lateral	fields	
had their anterior border at the symphysis pubis and 
the posterior border encompassed the entire sacral 
silhouette. A total dose of 50 Gy was prescribed 
in 25 equal fractions to the isocenter. HDR-ICBT 
using a Microselectron (Nucletron International, 
Amsterdam, Netherlands) followed by EBRT in two 
fractions (850 cGy/fraction) at point A. Cisplatin was 
administered at dose of 40 mg/m2 on day 1, 8, 15, 
22, and 29; 2 hours or less prior to EBRT treatment 
given concurrently on the same days (Pearcey et al. 
2002; Elizabeth et al. 2006; Palmer et al. 2012).
 Clinical Chemoradiotherapy Response. 
Clinical response to radiation treatment was evaluated 
by	a	 radiotherapist	 and	classified	according	 to	 the	
Hong Criteria (Gonzalez et al. 2002) as follows: (i) 
NRT (no gross residual tumor); complete or nearly 
complete	 regression	of	 pelvic	 tumor;	 non	 specific	
fibrosis;	or	granulation	over	the	cervix.			These	results	
are designated in our research as a positive (good) 
clinical response to treatment. (ii) GT response 
(gross residual tumor): gross tumor or palpable 
nodularity on cervix, and/or palpable in duration on 
the parametrium. These results are designated as a 
negative (bad) clinical response to treatment.
 Immunohistochemistry. The p53 index and 
expression of Akt were analyzed by performing 
immunohistochemistry of pre-treatment biopsy 
samples. These samples of tumor tissue were 
embedded in paraffin, then incubated with Akt 
antibody (Abcam, USA) applied at a 1:100 dilution 
and with anti p53 monoclonal antibody (Leica, 
Novocastra, ready to used-p53-D07), over night at 5 
oC, in a moist chamber, followed by post primary, post 
protein, and Novolink HRP system (Novolink) and 
revealed with DAB (Novolink) and counterstained 
with Mayer Hematoxylin. The primary antibody 
was omitted in one of slide as a negative control. 
Staining for p53, observed in the nucleus, was 
scored as percent of stained cells (Kurnia et al. 
2009).  Up to 1000 cells were counted in each slide. 
Expression of Akt found in nucleus, cell cytoplasm 
and membrane, was observed in zones of maximum 
expression of the marker in at least 10 high power 
fields	(400×).		Expression	of	Akt	was	described	using	
semi-quantitative scoring with the Immuno Reactive 
Score (IRS). The semi-quantitative analysis of the 
stained sections was carried out by light-microscopy 
and scored according to the IRS system introduced 
(Kaemerer et al. 2012) (Table 2).
 Statistical Analysis. The p53 index was analyzed 
by using the Kolmogorov test for normal distribution 
data. Statistical analysis was conducted to assess 
any correlation between the Akt IRS score and the 
p53 index. Analysis of variance (ANOVA) test was 
used to analyze the relationship between the Akt 
IRS score and the clinical response of subjects to 
chemoradiotherapy. All statistical analyses were 
performed using Medcalc Software Version 9.2.0.1 
(Harris & Taylor 2008). 
RESULTS
 In terms of clinical response to radiation treatment, 
14	patients	(70%)	showed	a	positive	clinical	response	
and	 6	 patients	 (30%)	 showed	 a	 negative	 clinical	
response after completion of treatment (Table 2). 
Our goal was to determine whether there exists any 
correlation between these outcomes with Akt and p53 
expression.
 Measures of both Akt and p53 expression were 
obtained from tumor samples from 20 subjects. 
Expression of Akt was observed as brown coloration 
in the cancer cell cytoplasm (Figure 1A,B,C) and 
Table	2.	Akt	and	IRS	classification	scoring	systems
Percentage of positive cells      Intensity of staining      IRS (0 – 12)
0 = no positive cells
1 <	10%	of	positive	cells
2	=	10-50%	positive	cells
3	=	51-80%	positive	cells
4 >	80%	positive	cells
0 = no colour reaction
1 = mild reaction
2 = moderate reaction
3 = intense reaction
0 – 1 = negative
2 – 3 = mild
4 – 8 = moderate
9 – 12 = strongly positive
IRS points                                           IRS	classification
0 – 1                                          
2 – 3                                          
4 – 8                                          
9 – 12                                         
0 = negative
1 = positive, weak expression
2 = positive, mild expression
3 = positive, strong expression
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Figure 1D as negative control. We observed strong 
expression	of	Akt	in	one	patient	(5%),	mild-positive	
expression	in	14	patients	(70%),	and	low	or	negative	
expression	of	Akt	in	5	patients	(25%).
 Patients who showed a positive clinical response 
to	radiation	treatment	were	#4	(28%)	showed	weak	
expression	 of	Akt,	 and	 #7	 (50%)	 showed	mild	
expressions of Akt. Patients who had a negative 
clinical	 response	 to	 radiation	 treatment,	 #1	 (14%)	
showed	strong	Akt	expression,	and	#6	(85	%)	showed	
mild expression of Akt.
 The expression of p53 protein can be observed as 
brown coloration in the nucleus (Figure 1E) and is 
measured as percentage of nucleus affected.  Among 
our research subjects, the p53 index varied from 
13	to	67%	(mean	41%).	As	shown	in	Figure	2,	we	
found no statistical correlation between expression 
of Akt and expression of p53 (P = 0.73, r = 0.08). 
We	did	find	a	significant	correlation	between	higher	
expression of Akt and negative clinical response (P 
= 0.03) and between higher expression of p53 and 
positive clinical response (P = 0.29) after completion 
of chemoradiotherapy. Our results indicate that high 
expression of Akt before treatment correlates to 
negative clinical responses in chemoradiotherapy 
treatment. 
DISCUSSION
 Expression of Akt in our patient samples can 
also be categorized as either positive, or weak/
negative	expression,	with	a	“positive”	defined	as	≥	
75%	of	cervical	cancer	tissue	testing	positive	for	Akt	
expression;	and	“weak/negative”	defined	as	≤	25%	of	
cancer tissue testing with low or no Akt expression. 
Other studies have analyzed pre-treatment tissues of 
patients with locally advanced cervical cancer and 
found	that	86%	(Kocak	et al.	2013),	and	74%	(Kim	et 
al.	2006),	classify	as	“positive”	for	Akt.	These	studies	
used a different method to analyze the expression of 
Akt,	which	classified	according	to	the	intensity	and	
quality of staining from Akt inside the cancer cell 
(Kim et al. 2006; Suzuki et al. 2010). In a study of 
glioblastoma (Suzuki et al. 2010) Akt was found in 
the	nucleus	as	well	in	cytoplasm,	with	29.7%	of	the	
subjects	categorized	as	50%	high	positive.
	 Our	results	showed	only	a	weak,	non-significant	
negative correlation between Akt and p53 expression. 
Prior research suggests that Akt will suppress 
expression of p53 related with mitochondria function. 
In wild-type p53, Akt clearly functions to modulate 
the direct action of p53 on the caspase-dependent 
mitochondrial function in death pathway (Yang et al. 
2006). The relationship between Akt and p53 activity 
 
 
 
 
 
20 mm
20 mm
20 mm
20 mm
20 mm
A
B
C
D
E
Figure 1. Expression of Akt is weak (A), medium (B) and 
strong (C) in cervical cancer tissues before treatment 
with chemoradiotherapy. Negative control (D) and 
expression of p53 (E).
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also	influenced	by	MDM2	function	by	degradation	of	
p53 protein (Zhou et al. 2001; Yoko et al. 2002; Milne 
et al. 2004).  Although almost all p53 mutations can 
be detected using immunohistochemical techniques, 
sequencing analysis is still necessary to ensure the 
type of DNA mutation.
 Expression of p53 and Akt each showed a 
different association with chemoradiotherapy 
clinical response. Higher expression of p53 tended 
to correlate with positive clinical response; it may 
be that mutated forms of p53 promote uncontrolled 
proliferation of cancer cells, which in turn increases 
radiosensitivity during the cell cycle phase, making 
the cells more susceptible to radiation than wild–
type p53. Researchers have observed resistance to 
chemotherapy and radiotherapy in NSCLC (non 
small cell lung carcinoma) cell lines, when Akt 
is highly expressed (Brognard et al. 2001). Other 
studies have sought to understand and clarify the 
relationship between Akt and clinical response, in 
head and neck cancer treated with radiotherapy, and 
breast cancer treated with chemotherapy. Clinical 
studies	have	confirmed	an	association	between	Akt	
expression and resistance to radiotherapy in head and 
neck tumors (Gupta et al. 2002) and to chemotherapy 
in breast cancer (Stall et al. 2003). In this study, we 
surmise that Akt may disrupt the apoptosis process 
induced by irradiation that should lead to cancer cell 
death. One study of Non Small Cell Lung Carcinoma 
(NSCLCs) also showed a correlation between high 
expression of Akt and indicators of poor prognosis, 
in NSCLCs with lymph-node involvement, but it 
can’t be considered to indicate distant of metastasis 
(Hirami et al. 2004).
 Radiation exposure produces highly reactive 
free radicals, such as reactive oxygen species, that 
can interact with and damage DNA interfering with 
the cell’s ability to reproduce normally. Reactive 
molecules may also affect intracellular functions 
such as cytokine production, growth factors, gene 
transcription, and apoptosis (Benz & Yau 2008; Flohe 
& Flohe 2011). Akt may contribute to treatment 
resistance by stimulating Non Homolog End Joining 
(NHEJ) repair and promoting cancer cell survival 
(Toulany et al. 2008) or by associating with DNA-
PK in response to genotoxic stresses (Bozulic et al. 
2008). Thus Akt can inhibit imminent cell death 
or apoptosis that would normally occur as a result 
of radiation treatment. PI3K/AKT signaling may 
influence	 clinical	 response	 to	 radiation	 in	 various	
ways, by altering regulation of mitochondrial proteins, 
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Figure 2. Corellation between expressio  of Akt, and p53 (A), 
expression of Akt (B), and p53 (C) in complete and 
partial response of chemoradiotherapy.
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C
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transcription factors, translation machinery, and cell-
cycle progression (Zhan & Han 2004; Cheung & 
Testa 2013). Our research clearly supports the idea 
that the level of Akt expression prior to treatment can 
serve as a parameter to predict positive or negative 
clinical response to chemoradiotherapy in cervical 
cancer cases. High expression of Akt correlates 
to increased resistance of cervical cancer cells to 
chemoradiotherapy. Pre-treatment measurements of 
Akt expression can be used as a biomarker of patient 
response to chemoradiotherapy for cervical cancer.
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